RS50972B - Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate - Google Patents

Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate

Info

Publication number
RS50972B
RS50972B RSP-2009/0327A RSP20090327A RS50972B RS 50972 B RS50972 B RS 50972B RS P20090327 A RSP20090327 A RS P20090327A RS 50972 B RS50972 B RS 50972B
Authority
RS
Serbia
Prior art keywords
tetrahydrofolate
methyl
estrogens
pharmaceutical composition
composition containing
Prior art date
Application number
RSP-2009/0327A
Other languages
English (en)
Inventor
Kai Strothmann
Gavin Welch Smith
Kristina King
Rudolf Moser
Klaus Pietrzik
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Merck Eprova Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50972(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Bayer Schering Pharma Aktiengesellschaft, Merck Eprova Ag. filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of RS50972B publication Critical patent/RS50972B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Lek naznačen time da sadrži- 5-metil-(6S)-tetrahidrofolat,- jedan ili više estrogena, odabranih iz grupe etinilestradiola , mestranola, kvinestranola estradiola, estrona, estrana, estriola, estetrola i konjugovanje ekvin estrogena i/ili gestagena,- opcionalno vitamin B6 i/ili vitamin B2,- kao i famaceutski podnošljive pomoćne/ noseće materije (punioci) uz odsustvo vitamina B12.Prijava sadrži još 47 patentnih zahteva.
RSP-2009/0327A 2005-05-13 2006-05-15 Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate RS50972B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
PCT/EP2006/004858 WO2006120035A2 (de) 2005-05-13 2006-05-15 Pharmazeutische zusammensetzung enthaltend gestagene und/oder estrogene und 5-methyl-(6s)-tetrahydrofolat

Publications (1)

Publication Number Publication Date
RS50972B true RS50972B (sr) 2010-10-31

Family

ID=37396913

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2009/0327A RS50972B (sr) 2005-05-13 2006-05-15 Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
RS20120325A RS52651B (sr) 2005-05-13 2006-05-15 Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20120325A RS52651B (sr) 2005-05-13 2006-05-15 Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate

Country Status (38)

Country Link
US (2) US20080160004A1 (sr)
EP (3) EP2298307A1 (sr)
JP (2) JP2008540482A (sr)
KR (2) KR101598735B1 (sr)
CN (2) CN101198332B (sr)
AR (1) AR054123A1 (sr)
AT (2) ATE429917T1 (sr)
AU (1) AU2006245921A1 (sr)
BR (1) BRPI0611443B8 (sr)
CA (1) CA2608639C (sr)
CL (2) CL2009002187A1 (sr)
CR (1) CR9531A (sr)
CY (2) CY1109261T1 (sr)
DE (1) DE502006003617D1 (sr)
DK (2) DK1888077T3 (sr)
DO (1) DOP2006000110A (sr)
EA (2) EA014664B1 (sr)
EC (1) ECSP078001A (sr)
ES (2) ES2325600T3 (sr)
GT (1) GT200600200A (sr)
HK (1) HK1118729A1 (sr)
HR (1) HRP20090418T1 (sr)
IL (1) IL187340A (sr)
MA (1) MA29448B1 (sr)
MY (1) MY147362A (sr)
NO (1) NO345807B1 (sr)
PE (1) PE20061415A1 (sr)
PL (2) PL1888077T3 (sr)
PT (2) PT1888077E (sr)
RS (2) RS50972B (sr)
SG (1) SG169973A1 (sr)
SI (2) SI2116249T1 (sr)
SV (1) SV2008002527A (sr)
TN (1) TNSN07418A1 (sr)
TW (1) TWI380820B (sr)
UY (1) UY29527A1 (sr)
WO (1) WO2006120035A2 (sr)
ZA (1) ZA200710811B (sr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CA2665788A1 (en) * 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
UY31010A1 (es) * 2007-04-05 2008-11-28 Bayer Schering Pharma Ag Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion
JP2011507853A (ja) * 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
WO2011128336A1 (en) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
KR102664563B1 (ko) 2015-06-18 2024-05-09 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
CA2988485A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
SI3310333T1 (sl) 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
US5997915A (en) 1996-01-31 1999-12-07 South Alabama Medical Science Foundation Compositions for human and animal consumption containing reduced folates and methods for making and using same
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
JP2002527484A (ja) * 1998-10-19 2002-08-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DK1380301T3 (da) 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
JP2004538262A (ja) * 2000-12-14 2004-12-24 タフツ ユニバーシティー 関節炎状態を治療するための化合物および方法
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
MXPA04008185A (es) * 2002-02-21 2004-11-26 Schering Ag Composiciones farmaceuticas que comprenden uno o mas esteroides, uno o mas componentes de tetrahidrofolato y vitamina b12.
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
JP2013166753A (ja) 2013-08-29
CA2608639A1 (en) 2006-11-16
AU2006245921A1 (en) 2006-11-16
DOP2006000110A (es) 2012-06-15
EA028530B1 (ru) 2017-11-30
CL2009002187A1 (es) 2010-10-01
CR9531A (es) 2008-02-21
DK2116249T3 (da) 2012-08-20
ES2325600T3 (es) 2009-09-09
EA200702349A1 (ru) 2008-04-28
EA200901393A1 (ru) 2010-02-26
MY147362A (en) 2012-11-30
SG169973A1 (en) 2011-04-29
ATE555791T1 (de) 2012-05-15
HRP20090418T1 (en) 2009-09-30
EP2116249A1 (de) 2009-11-11
US10463666B2 (en) 2019-11-05
DK1888077T3 (da) 2009-08-17
JP5883810B2 (ja) 2016-03-15
RS52651B (sr) 2013-06-28
ES2387525T5 (es) 2024-07-05
SV2008002527A (es) 2008-03-27
MA29448B1 (fr) 2008-05-02
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
CA2608639C (en) 2013-04-30
PL2116249T3 (pl) 2013-06-28
PT2116249E (pt) 2012-08-07
EP2116249B1 (de) 2012-05-02
BRPI0611443B1 (pt) 2020-07-21
JP2008540482A (ja) 2008-11-20
NO345807B1 (no) 2021-08-16
ZA200710811B (en) 2012-06-27
BRPI0611443A2 (pt) 2010-09-08
TNSN07418A1 (en) 2009-03-17
EP2116249B2 (de) 2023-04-05
ECSP078001A (es) 2008-01-23
KR20140069175A (ko) 2014-06-09
PT1888077E (pt) 2009-07-20
CY1109261T1 (el) 2014-07-02
US20160095860A1 (en) 2016-04-07
EP1888077B1 (de) 2009-04-29
WO2006120035A2 (de) 2006-11-16
SI1888077T1 (sl) 2009-10-31
IL187340A (en) 2015-03-31
CL2010000989A1 (es) 2011-02-18
TW200711651A (en) 2007-04-01
EP1888077A2 (de) 2008-02-20
SI2116249T1 (sl) 2013-02-28
DE502006003617D1 (de) 2009-06-10
WO2006120035A3 (de) 2007-02-15
ES2387525T3 (es) 2012-09-25
CY1114403T1 (el) 2016-08-31
EA014664B1 (ru) 2010-12-30
TWI380820B (zh) 2013-01-01
GT200600200A (es) 2007-03-23
CN101198332B (zh) 2012-07-18
BRPI0611443B8 (pt) 2021-05-25
KR101598735B1 (ko) 2016-03-02
NO20076408L (no) 2008-02-12
KR20080028369A (ko) 2008-03-31
UY29527A1 (es) 2006-12-29
PL1888077T3 (pl) 2009-12-31
IL187340A0 (en) 2011-08-01
PE20061415A1 (es) 2007-01-26
US20080160004A1 (en) 2008-07-03
AR054123A1 (es) 2007-06-06
EP2298307A1 (de) 2011-03-23
ATE429917T1 (de) 2009-05-15
HK1118729A1 (en) 2009-02-20

Similar Documents

Publication Publication Date Title
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
HUP0204137A2 (hu) Fulvesztrantot tartalmazó gyógyászati készítmény
HRP20070188A2 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
CO6160297A2 (es) Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina
KR970706001A (ko) 습식-과립화를 통해 투여단위를 제조하는 방법 (process of making dosage units by wet granulation)
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
DE122007000011I1 (de) Feste Arzneiformen, enthaltend Clathrate vom steroidalen Sexualhormon Ethinylestradiol
HRP20100513T1 (en) Multi-phase contraceptive preparation based on a natural estrogen
AU2003253506A1 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
DE60017281D1 (de) Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung
CY1108265T1 (el) Στερεη διαστοματικη φαρμακευτικη μορφη για αντισυλληψη
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
TW200638951A (en) Solid oral pharmaceutical form for contraception
HRP20040611B1 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
SI20851B (sl) Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)
DK1937274T3 (da) Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
AR069195A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
RU2009140372A (ru) Новый режим с дроспиреноном/17b-эстрадиолом, фармацевтический комбинированный продукт и набор для выполнения этого режима